Peptidomimetic blockade of MYB in acute myeloid leukemia
Kavitha Ramaswamy(Memorial Sloan Kettering Cancer Center), Alex Kentsis(Memorial Sloan Kettering Cancer Center)
Cited by 95
Related Papers
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor
|JCI Insight|2019|29
Peptidomimetic blockade of MYB in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2017|11
KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in <i>NUP98</i> -Rearranged Acute Myeloid Leukemia
|Cancer Discovery|2025|11
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2017|8
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
|Journal of Clinical Investigation|2025|4